Can a new injectable drug safely tackle weight? an early trial seeks answers
NCT ID NCT07721597
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether an experimental drug called ZP6590 is safe and how the body processes it. The study includes men with normal weight, overweight, and obesity. Some participants receive a single dose of ZP6590 or a placebo, while others receive multiple doses over several weeks. The goal is to gather initial safety data and understand how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental injectable drug called ZP6590
- What this could lead to
- If safe and well-tolerated, ZP6590 could become a new option for weight management.
- What could go wrong
- This is a very early, first-in-human trial with only 88 participants, so safety and effectiveness are not yet known. Side effects may emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST IN MAN STUDY TO EVALUATE INITIAL SAFETY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil, Institut für Stoffwechselforschung GmbH
RECRUITINGNeuss, North Rhine-Westphalia, 41460, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental biologic CND319 takes first steps toward taming autoimmune diseases
- Scientists map brain changes during Hour-Long DMT experience
- First human trial launches for experimental drug BY002
- Leucine: the Muscle-Saving supplement for dieters?
- New drug BW-50218 put to first safety test in healthy chinese volunteers
- New COPD drug candidate AN01 begins first human safety tests